ArticleDiscover oncology2025
DCUN1D5 is a novel potential biomarker for predicting the prognosis of bladder cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DCUN1D5 as a New Biomarker and Regulator of Fatty Acid Metabolism in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Bladder cancer is a malignant tumor ranks among the most common urogenital malignancies. Treatment efficacy specifically in MIBC remains suboptimal due to profound tumor heterogeneity. Gene and protein biomarkers provide the opportunity for precise diagnosis and treatment. In this study, by using bioinformatic portals, we identified DCUN1D5 as an upregulated gene that may influence pan-cancer prognosis. Its expression showed significant differences across histological grades and tumor subtypes in BLCA. We found that co-expression genes of DCUN1D5 were enriched in translation initiation factor activity and methyltransferase activity, suggesting potential regulatory mechanisms of DCUN1D5. Furthermore, we validated the prognostic role of DCUN1D5 in BLCA through immunohistochemical analysis of 56 tissue microarray samples. The relationship between DCUN1D5 expression and clinicopathological parameters of BLCA was analyzed by Chi-square test, and result was consistent with bioinformatic analysis. In conclusion, we identified DCUN1D5 as a novel potential Biomarker for predicting the prognosis of BLCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.